Page 91

Abril_2107

499 artículo de revisión Farmacogenómica, medicina personalizada y la práctica clínica - L. Quiñones et al Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther 2014; 95 (5): 499-500. 24. Crews KR, Hicks JK, Pui C-H, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012; 92 (4): 467-75. 25. Agúndez JAG, Abad-Santos F, Aldea A, Alonso-Navarro H, Bernal ML, Borobia AM, et al. Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Front Genet 2012; 3: 273. 26. Roco Á, Quiñones L, Agúndez JAG, García-Martín E, Squicciarini V, Miranda C, et al. Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population : comparison with Caucasian and Asian populations. 2012; 3: 1-9. 27. Spear B, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7 (5): 201-4. 28. Quiñones L, Lee K, Varela FN, Escala M, García K, Godoy L, et al. Cancer pharmacogenetics: study of genetically determined variations on cancer susceptibility due to xenobiotic exposure. Rev Med Chile 2006; 134 (4): 499-515. 29. Cypalleles.ki.se Internet. The Human Cytochrome P450 (CYP) Allele Nomenclature Database citado el 20 de mayo de 2016. Disponible en: http://www.cypalleles. ki.se 30. Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, et al. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther 2016; 99 (2): 172-85. 31. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348 (6): 529-37. 32. Umamaheswaran G, Kumar DK, Adithan C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters-a review with Indian perspective. Indian J Med Res 2014; 139 (1): 27-65. 33. Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacký, Olomouc, Czechoslov 2010; 154 (2): 103-16. 34. Yiannakopoulou EC. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications. Pharmacogenomics J 2013; 13 (2): 105-9. 35. Varela N, Quiñones LA, Stojanova J, Garay J, Cáceres D, Cespedes S, et al. Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses. Pharmacol Res 2015; 101: 124-9. 36. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250 (3): 186-200. 37. Rodríguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006; 25 (11): 1679-91. 38. Huang B, Jiang C, Zhang R. Epigenetics: the language of the cell? Epigenomics 2014; 6 (1): 73-88. 39. Yu A-M, Tian Y, Tu M-J, Ho PY, Jilek JL. MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy. Drug Metab Dispos 2016; 44 (3): 308-19. 40. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6 (2): 117-29. 41. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90 (4): 625-9. 42. da Silva Nogueira J, de Lima Marson FA, Sílvia Bertuzzo C. Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer. BMC Res Notes 2012; 5: 676. 43. Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, et al. A candidate gene study of capecitabine related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut 2015; 64 (1): 111-20. 44. 1000 Genomes Project Internet. c2015; citado el 20 de mayo de 2016. Disponible en: http://browser.1000genomes. org/index.html 45. Kimchi-Sarfaty C, Oh JM, Kim I-W, Sauna ZE, Calcagno AM, Ambudkar S V, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315 (5811): 525-8. 46. Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/ MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 2013; 24 (6): 1513-25. 47. Xu G, Bhatnagar V, Wen G, Hamilton BA, Eraly SA, Nigam SK. Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST). Kidney Int 2005; 68 (4): 1491-9. 48. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Rev Med Chile 2017; 145: 483-500


Abril_2107
To see the actual publication please follow the link above